Medicina de Família
Estudo randomizado | Carboximaltose férrica IV vs. fumarato ferroso por via oral em crianças anêmicas com doença inflamatória intestinal
31 Jan, 2023 | 11:51h
Estudo randomizado | Efeitos de um sistema orientado pela web para autotratamento da vertigem posicional paroxística benigna recorrente
23 Jan, 2023 | 13:42hEffect of Self-treatment of Recurrent Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial – JAMA Neurology (gratuito por tempo limitado)
Vídeo relacionado: Web-Guided Canalith Reposition Maneuver – JAMA
Comentário: Web-Based System Works Well for Diagnosis, Treatment of Recurrent Vertigo – HealthDay
Comentário no Twitter
Patients may benefit from treating benign paroxysmal positional vertigo themselves using a web-guided system. https://t.co/9Hjwb0XGnl
— JAMA Neurology (@JAMANeuro) January 20, 2023
Prescrição em cascata: como detectar, evitar e usar essa estratégia adequadamente
23 Jan, 2023 | 13:39hConteúdos relacionados:
Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain – Journal of the American Geriatrics Society (link para o resumo – $ para o texto completo)
Are you the victim of a prescribing cascade?
Prescribing Cascade in a Cardiology Practice
Estudo randomizado | Furoato de mometasona intanasal e salina são similarmente efetivos para distúrbios respiratórios do sono em crianças
23 Jan, 2023 | 13:37hEffectiveness of Intranasal Mometasone Furoate vs Saline for Sleep-Disordered Breathing in Children: A Randomized Clinical Trial – JAMA Pediatrics (gratuito por tempo limitado)
Comunicado de imprensa: Simple nasal spray significantly reduces snoring and breathing difficulties in children – Murdoch Childrens Research Institute
Comentário: Pediatric Sleep-Disordered Breathing Managed in Primary Care with Corticosteroid or Saline – HCP Live
Comentário no Twitter
Study suggests that in primary care, first-line treatment of sleep-disordered breathing in children could include 6 weeks of intranasal saline, or corticosteroid, which may resolve symptoms in almost one-half of children. https://t.co/oWrwcjgkPS @kirstenperrett
— JAMA Pediatrics (@JAMAPediatrics) January 17, 2023
Estudo de coorte | Prevalência da neoplasia colorretal 10 ou mais anos após uma colonoscopia de rastreamento negativa em 120.000 repetições desses exames
23 Jan, 2023 | 13:34hComentários:
Prevalence of Colorectal Cancers Low 10 Years Following Negative Screening Test – HCP Live
Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy – HealthDay
Comentário no Twitter
Large registry-based study finds strong potential for risk-adapted #colorectalcancer screening, suggests extension of screening endoscopy intervals beyond 10 years may be warranted particularly in asymptomatic female and younger participants. https://t.co/fChg6DRyPw @DKFZ
— JAMA Internal Medicine (@JAMAInternalMed) January 17, 2023
Breve revisão e algoritmo | Tratamento da tuberculose latente
23 Jan, 2023 | 13:31hManagement of Latent Tuberculosis Infection – JAMA (gratuito por tempo limitado)
Revisão | Desfechos cardiovasculares no diabetes tipo 1 e tipo 2
23 Jan, 2023 | 13:07hCardiovascular outcomes in type 1 and type 2 diabetes – Diabetologia
Comentário no Twitter
Useful review of Cardiovascular outcomes in type 1 and type 2 diabeteshttps://t.co/mDECkFbZCq pic.twitter.com/q7J74FkNgJ
— Prof Kamlesh Khunti (@kamleshkhunti) January 20, 2023
Artigo sob licença de http://creativecommons.org/licenses/by/4.0/.
OMS atualiza diretrizes de COVID-19 sobre máscaras, tratamentos e cuidados do paciente
16 Jan, 2023 | 11:17hWHO updates COVID-19 guidelines on masks, treatments and patient care – World Health Organization
Diretrizes OMS atualizadas:
Therapeutics and COVID-19: Living guideline, 13 January 2023 – World Health Organization
Estudo randomizado | Fluvoxamina não é melhor que placebo em pacientes ambulatoriais com COVID-19 leve a moderada
16 Jan, 2023 | 11:12hEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Entrevista com a autora: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Comentário: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Comentário no Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023
Melhores artigos de 2022 sobre doenças infecciosas – Uma revisão de fim de ano da literatura não COVID
16 Jan, 2023 | 11:06h
Comentário no Twitter
🔥🔥NEW 🔥🔥
Our new post, a great collaboration w 🌟 @IDstewardship
Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
1️⃣7️⃣⚡️🆔 RCTs @NEJM @TheLancet ✨
2️⃣syst Rev
3️⃣🌏Guidelines @Wiki_Guidelines
#IDTwitter #TwitteRxhttps://t.co/JL07NLa3BV pic.twitter.com/Qcf2cwK8Sd— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 4, 2023